Could a lower dose of this antibody tame Slow-Growing lymphoma?

This phase II trial is testing whether a low dose of the drug mosunetuzumab can safely and effectively treat people with slow-growing B-cell lymphomas, like follicular and marginal zone lymphoma. The study will enroll 20 adults who have not had prior lymphoma therapy and have low-tumor burden disease. Researchers will monitor tumor shrinkage and side effects to see if this approach offers a less intense treatment option.